RxDoctor Payments DataLook up a doctor →

Nilesh Lodhia, MD

Gastroenterology · Charlotte, NCNPI 1922264654

Payments from drug & device makers

$1,201,536in general payments, 2019–2025

Across 1,455 payments — averaging $825.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$537K
  • E.r. Squibb & Sons, L.L.C.$176K
  • Johnson & Johnson$176K
  • Pfizer$78K
  • Janssen Scientific Affairs, LLC$71K
  • Bristol Myers Squibb$60K
  • plus $104K from 18 others

What the payments were for

  • Consulting fees$17,7332%
  • Speaking & faculty fees$602,24582%
  • Travel & lodging$82,26111%
  • Food & beverage$32,5724%
  • Education$1870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,201,536 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$36,246
Medicare patients
164
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab83$2,246,434
Skyrizi On-BodyRisankizumab-Rzaa61$1,195,742
Humira(Cf) PenAdalimumab63$922,083
RinvoqUpadacitinib40$378,583
LinzessLinaclotide21$20,928
Mesalamine15$10,608
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates92$6,064
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag37$4,617
Omeprazole101$2,274
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C15$2,058
Colesevelam Hcl13$1,272
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl57$877
Pantoprazole Sodium47$802
Diphenhydramine Hcl51$736
Esomeprazole Magnesium14$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$175,748$2,246,43483 claims
AbbVieRinvoq, Linzess$537,232$399,51161 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$482$2,05815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →